Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study
Background: Effective treatments are urgently needed for HCC after progression on
ICI-based therapies. FGF19+ is in w 30% HCC and associated with poor prognosis.
Irpagratinib, an oral and highly selective FGFR4 inhibitor, has demonstrated promising
anti-tumor activity in HCC. Here, we report the updated results of phase 2 study
(NCT05441475) with more patients (pts) at recommended dose of expansion.
第一作者机构：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Oncol, Chibi City, Peoples R China
推荐引用方式(GB/T 7714)：
Cheng Q.,Zhang Y.,Wang J.,et al.Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study[J].ANNALS OF ONCOLOGY.2025,36:S63-S63.doi:10.1016/j.annonc.2025.05.162.
APA：
Cheng, Q.,Zhang, Y.,Wang, J.,Zhao, L.,Hou, C....&Chen, X-P.(2025).Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study.ANNALS OF ONCOLOGY,36,
MLA：
Cheng, Q.,et al."Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011-201 study".ANNALS OF ONCOLOGY 36.(2025):S63-S63
医学